이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Theracryf 미래 성장

Future 기준 확인 0/6

Theracryf 의 수익은 연간 150.1% 감소할 것으로 예상되는 반면, 연간 수익은 30.7% 로 증가할 것으로 예상됩니다. 30.7% 연간. EPS는 연간 55.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -131.5% 로 예상됩니다.

주요 정보

30.7%

수익 성장률

55.5%

EPS 성장률

Biotechs 수익 성장	27.8%
매출 성장률	-150.1%
향후 자기자본 수익률	-131.5%
애널리스트 커버리지	Low
마지막 업데이트	14 Jun 2024

최근 미래 성장 업데이트

Recent updates

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Oct 11

We're Hopeful That Evgen Pharma (LON:EVG) Will Use Its Cash Wisely

Nov 24

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Aug 06

Is Evgen Pharma (LON:EVG) In A Good Position To Deliver On Growth Plans?

Apr 09

We're Keeping An Eye On Evgen Pharma's (LON:EVG) Cash Burn Rate

Dec 25

수익 및 매출 성장 예측

AIM:TCF - 애널리스트의 미래 추정치 및 과거 재무 데이터 (GBP Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
3/31/2026	N/A	-2	-2	-2	2
3/31/2025	N/A	-1	-1	-1	2
3/31/2024	0	-3	-3	-3	N/A
12/31/2023	1	-3	-3	-3	N/A
9/30/2023	1	-3	-4	-4	N/A
6/30/2023	1	-4	-4	-4	N/A
3/31/2023	0	-4	-4	-4	N/A
12/31/2022	0	-4	-4	-4	N/A
9/30/2022	N/A	-3	-3	-3	N/A
6/30/2022	N/A	-3	-3	-3	N/A
3/31/2022	N/A	-3	-3	-3	N/A
12/31/2021	N/A	-3	-3	-3	N/A
9/30/2021	N/A	-2	-3	-3	N/A
6/30/2021	0	-3	-3	-3	N/A
3/31/2021	0	-3	-3	-3	N/A
12/31/2020	0	-3	-3	-3	N/A
9/30/2020	0	-3	-3	-3	N/A
6/30/2020	0	-3	-3	-3	N/A
3/31/2020	N/A	-3	-3	-3	N/A
12/31/2019	N/A	-3	-3	-3	N/A
9/30/2019	N/A	-2	-2	-2	N/A
6/30/2019	N/A	-3	-2	-2	N/A
3/31/2019	N/A	-3	-2	-2	N/A
12/31/2018	N/A	-3	-2	-2	N/A
9/30/2018	N/A	-3	-2	-2	N/A
6/30/2018	N/A	-3	-2	-2	N/A
3/31/2018	N/A	-3	-2	-2	N/A
12/31/2017	N/A	-3	N/A	-3	N/A
9/30/2017	N/A	-3	N/A	-3	N/A
6/30/2017	N/A	-3	N/A	-3	N/A
3/31/2017	N/A	-3	N/A	-3	N/A
12/31/2016	N/A	-3	N/A	-3	N/A
9/30/2016	N/A	-4	N/A	-3	N/A
6/30/2016	N/A	-3	N/A	-2	N/A
3/31/2016	N/A	-3	N/A	-2	N/A
12/31/2015	N/A	-3	N/A	-1	N/A
9/30/2015	N/A	-2	N/A	-1	N/A
6/30/2015	N/A	-2	N/A	-1	N/A
3/31/2015	N/A	-2	N/A	-1	N/A

애널리스트 미래 성장 예측

수입 대 저축률: TCF 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: TCF 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: TCF 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: TCF 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 수익: TCF 은(는) 내년에 수익이 없을 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: TCF (는) 3년 내에 수익성이 없을 것으로 예상됩니다.

Theracryf 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Consensus revenue estimates fall by 92%

Consensus forecasts updated

Recent updates

Theracryf Plc, Annual General Meeting, Jul 18, 2024

Theracryf Plc to Report Fiscal Year 2024 Results on May 28, 2024

New minor risk - Financial data availability

Evgen Pharma plc has completed a Follow-on Equity Offering in the amount of £0.05167 million.

Evgen Pharma plc has filed a Follow-on Equity Offering in the amount of £1 million.

Evgen Pharma plc Announces That the Laboratories of Professor Grace Chen, Associate Professor Justin Colacino, and Professor Duxin Sun At the University of Michigan, Usa Have Observed Activity of Sfx-01 in Models of Colon Cancer

Evgen Pharma plc Announces That the Laboratory of Dr Marjolein Geurts, Neuro-Oncologist At the Erasmus University Medical Centre Has Observed Continuing Activity of Sfx-01 in Gbm Cells

Evgen Pharma plc announced that it has received $17.4 million in funding from Stalicla SA

New minor risk - Share price stability

Evgen Pharma plc Appoints Toni hänninen as Permanent Chief Financial Officer, Effective 1 January 2024

Evgen Pharma plc Announces Erasmus Medical Center Commences Sfx-01 Glioblastoma Studies

Evgen Pharma plc Announces Executive Changes

Evgen Pharma plc Announces Final Clinical Study Report from Phase 1B PK/PD Study of New SFX-01 Tablet Formulation Approved

New major risk - Market cap size

New minor risk - Share price stability

Evgen Pharma plc, Annual General Meeting, Jul 20, 2023

Consensus revenue estimates fall by 92%

Evgen Pharma plc to Report Q4, 2023 Results on Jun 07, 2023

Evgen Pharma plc Announces Update on Study to Investigate Performance of New SFX-01 Tablet Formulation - All Cohorts Dosed

Consensus forecasts updated

Evgen Pharma plc to Report First Half, 2023 Results on Dec 08, 2022

Insufficient new directors

Evgen Pharma plc Announces Clinical Trial Update

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Evgen Pharma plc Receives Regulatory and Ethical Approvals for A Healthy Volunteer, Pharmacokinetic and Pharmacodynamic, Study Toexamine the Performance of the Company's New Enteric Coated Tablet Formulation of Lead Asset SFX-01

Evgen Pharma plc, Annual General Meeting, Jul 21, 2022

Evgen Pharma plc to Report Fiscal Year 2022 Results on Jun 08, 2022

Insufficient new directors

Evgen Pharma plc Announces Progress Discussions with the UK Medicines and Healthcare Products Regulatory Agency and the US Food and Drug Administration

Insufficient new directors

We're Hopeful That Evgen Pharma (LON:EVG) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Evgen Pharma's (LON:EVG) Cash Burn Situation

Evgen Pharma plc Announces Early Data for SFX-01 in Leukaemia Cell Lines

Evgen Pharma plc Announces Glioma Orphan Drug Application Submitted to US FDA

Evgen Pharma plc Announces Progress on Metastatic Breast Cancer Programme

Is Evgen Pharma (LON:EVG) In A Good Position To Deliver On Growth Plans?

Evgen Pharma plc Provides Update on Data Safety Review for STAR COVID-19 Trial

Evgen Pharma plc Updates on Patient Recruitment

Evgen Pharma plc, Annual General Meeting, Mar 03, 2021

We're Keeping An Eye On Evgen Pharma's (LON:EVG) Cash Burn Rate

Evgen Pharma plc to Report Fiscal Year 2020 Results on Jun 15, 2020

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견